Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Explore this paper's citation graph
Summary
Pembrolizumab was associated with significantly longer overall survival and with a lower rate of treatment‐related adverse events than chemotherapy as second‐line therapy for platinum‐refractory advanced urothelial carcinoma.
- Type
- article
- Published
- 2017-02-17
- Cited by
- 2,885
- References
- 26
- Access
- Open access
- OpenAlex
- https://openalex.org/W2588916311
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:205101259
Keywords
Medicine, Pembrolizumab, Hazard ratio, Internal medicine, Docetaxel
References
- Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials
- Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
- Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
- Molecular biology and targeted therapies for urothelial carcinoma.
- Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.
- Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer
- Global cancer statistics
- Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.
- Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.
- Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy.
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
- Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial
- [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.
- Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.
- The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis
- The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis
- Gene expression profiling to predict responsiveness to immunotherapy
Cited by
- Toward personalized management in bladder cancer: the promise of novel molecular taxonomy
- Atezolizumab in invasive and metastatic urothelial carcinoma
- Immunotherapy in the Elderly.
- Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
- Correlation between sex and efficacy of immune checkpoint inhibitors (PD‐1 and CTLA‐4 inhibitors)
- Modulating T-cell-based cancer immunotherapy via particulate systems
- Clinical Features and Risk Factors of Skeletal-Related Events in Genitourinary Cancer Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial Carcinoma
- Cyclophosphamide with or without fluorouracil followed by subcutaneous or intravenous interleukin‐2 use in solid tumors: A feasibility off‐label experience
- Molecular markers in bladder cancer
- Targeting PD-L1 Protein: Translation, Modification and Transport.
- Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials.
- Cochrane Rapid Reviews: Immun-Checkpoint-Inhibitor Pembrolizumab vs. Chemotherapie zur Behandlung von fortgeschrittenen Urothelkarzinomen
- PD-L1 expression and correlation with outcome in muscle-invasive and metastatic urothelial carcinoma: review and critical discussion
- Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.
- Tumoren van de urinewegen
- Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma
- Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer
- Bladder cancer: Pembrolizumab is superior to chemotherapy
- Mechanistic and pharmacologic insights on immune checkpoint inhibitors
- Immunotherapy: a new treatment paradigm in bladder cancer
Related papers
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer
- Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR
- Glucosylsphingosine concentration is the most reliable response-parameter for low-dose ERT in homozygous N370S Gaucher patients
- Survival impact of compliance in extra-perigastric lymphadenectomy for gastric cancer: 20 years of real-world data from a single institution.
- The prognostic value of survivin expression in patients with colorectal carcinoma: a meta-analysis.
- Clinical characteristics, genotype and outcome of Gaucher disease in Pakistani children
- Job syndrome
- Excision margins in high-risk malignant melanoma.
- A pilot study of high-risk screening for neuronopathic Gaucher disease in Japan
- Newborn screening for Gaucher disease and MPS I disease: A single center experience in Taiwan